Paper42898005PubMed
Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.
Rosenberg A and 9 others. Eur J Neurol, 2026.
Cite this record
ConductScience Library. Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics. Papers, record 42898005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42898005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.
- Journal
- Eur J Neurol
- Year
- 2026
- Publication types
- Journal Article, Multicenter Study
- Revised in PubMed
- 2026-10-22
Source PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Amyloid beta-Peptides | Major topic |
| Cognitive Dysfunction | Major topic |
| Eligibility Determination | Major topic |
| Humans | |
| Sweden | |
| Female | |
| Male | |
| Aged | |
| Aged, 80 and over | |
| Cohort Studies |
Source PubMed
Grants11
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 101112145 | Innovative Health Initiative | PubMed | ||
| 101132933 | Innovative Health Initiative | PubMed | ||
| Region Stockholm (ALF) | PubMed | |||
| FoUI-104172 | Center for Innovative Medicine | PubMed | ||
| 357810 | EU Joint Programme - Neurodegenerative Disease Research | PubMed | ||
| AF-1031812 | Alzheimerfonden | PubMed | ||
| 2025-02405 | Vetenskapsrådet | PubMed | ||
| Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse | PubMed | |||
| FO2026-0228 | Hjärnfonden | PubMed | ||
| 2025-02071 | Forskningsrådet om Hälsa, Arbetsliv och Välfärd | PubMed | ||
| 2025-03749 | VINNOVA | PubMed |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41957377 | Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer's disease continuum. | Nat Commun | 2026 | https://conductscience.org/library/papers/41957377 | PubMed |
| 2 | 40155270 | Donanemab: Appropriate use recommendations. | J Prev Alzheimers Dis | 2025 | https://conductscience.org/library/papers/40155270 | PubMed |
| 3 | 37481563 | Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis. | Alzheimers Res Ther | 2023 | https://conductscience.org/library/papers/37481563 | PubMed |
| 4 | 41732200 | Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline. | Lancet Reg Health Eur | 2026 | https://conductscience.org/library/papers/41732200 | PubMed |
| 5 | 38862265 | Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease. | J Neurol Neurosurg Psychiatry | 2024 | https://conductscience.org/library/papers/38862265 | PubMed |
| 6 | 40058984 | Developing Treatment Models for the Delivery of the Antiamyloid Therapy, Lecanemab: Considerations for Implementation of Lecanemab in Healthcare Systems. | Am J Geriatr Psychiatry | 2025 | https://conductscience.org/library/papers/40058984 | PubMed |
| 7 | 9058064 | Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. | Eur Neurol | 1997 | https://conductscience.org/library/papers/9058064 | PubMed |
| 8 | 37459141 | Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37459141 | PubMed |
| 9 | 38593394 | Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study. | Neurology | 2024 | https://conductscience.org/library/papers/38593394 | PubMed |
| 10 | 40997839 | Treatment for Alzheimer's disease. | Lancet | 2025 | https://conductscience.org/library/papers/40997839 | PubMed |
| 11 | 40011174 | Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease. | J Prev Alzheimers Dis | 2025 | https://conductscience.org/library/papers/40011174 | PubMed |
| 12 | 39308280 | Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population. | BJPsych Open | 2024 | https://conductscience.org/library/papers/39308280 | PubMed |
| 13 | 32138686 | The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment. | BMC Geriatr | 2020 | https://conductscience.org/library/papers/32138686 | PubMed |
| 14 | 41225766 | Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations. | Alzheimers Dement | 2025 | https://conductscience.org/library/papers/41225766 | PubMed |
| 15 | 41544372 | Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. | J Prev Alzheimers Dis | 2026 | https://conductscience.org/library/papers/41544372 | PubMed |
| 16 | 1431963 | Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. | J Neurol Neurosurg Psychiatry | 1992 | https://conductscience.org/library/papers/1431963 | PubMed |
| 17 | 37357274 | Editorial: Lecanemab: Appropriate Use Recommendations - A Commentary from a European Perspective. | J Prev Alzheimers Dis | 2023 | https://conductscience.org/library/papers/37357274 | PubMed |
| 18 | 29653606 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Alzheimers Dement | 2018 | https://conductscience.org/library/papers/29653606 | PubMed |
| 19 | 37586881 | Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. | Neurology | 2023 | https://conductscience.org/library/papers/37586881 | PubMed |
| 20 | 36130840 | β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. | Neurology | 2022 | https://conductscience.org/library/papers/36130840 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42898005
GET https://conductscience.org/api/papers/v1/42898005/references?page=2